{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "f97bb779",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Libraries imported and environment loaded.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "import os\n",
    "import json\n",
    "import tempfile\n",
    "from typing import Annotated, Literal, TypedDict, List, Dict, Any\n",
    "import re\n",
    "\n",
    "# Environment and Document Libraries\n",
    "from dotenv import load_dotenv\n",
    "from reportlab.lib.pagesizes import letter\n",
    "from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer\n",
    "from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle\n",
    "\n",
    "from docx import Document\n",
    "\n",
    "# LangChain & LangGraph Core\n",
    "from langgraph.graph import StateGraph, START, END\n",
    "from langgraph.prebuilt import create_react_agent\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.tools import tool\n",
    "\n",
    "# LLMs and Tools\n",
    "from langchain_groq import ChatGroq\n",
    "from langchain_community.tools.pubmed.tool import PubmedQueryRun\n",
    "from langchain_community.tools.tavily_search import TavilySearchResults\n",
    "\n",
    "# Load environment variables from .env file\n",
    "load_dotenv()\n",
    "print(\"Libraries imported and environment loaded.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "9b1cc9b2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# This TypedDict defines the structure of our application's state.\n",
    "# It's the central memory that all agents share and can modify.\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    messages: Annotated[list[Any], \"The messages in the conversation\"]\n",
    "    original_query: str\n",
    "    research_results: Dict[str, Any]\n",
    "    # A list to keep track of which researchers have already run to avoid infinite loops.\n",
    "    completed_researchers: List[str]\n",
    "    # The final combined report text generated by the reporting node.\n",
    "    report: str\n",
    "    # The final output string containing file paths of the generated documents.\n",
    "    final_output: str\n",
    "    # A field to hold the decision from the reflection node about which agent to run next.\n",
    "    next_agent: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9e16c895",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "LLM and Tools initialized.\n"
     ]
    }
   ],
   "source": [
    "# We initialize our LLM and all the tools the agents will need.\n",
    "\n",
    "# LLM from Groq - fast and capable for agentic tasks.\n",
    "# llm = ChatGroq(model=\"gemma2-9b-it\", temperature=0)\n",
    "llm = ChatGroq(model=\"qwen/qwen3-32b\", temperature=0)\n",
    "\n",
    "# Research Tools\n",
    "pubmed_tool = PubmedQueryRun()\n",
    "tavily_tool = TavilySearchResults(max_results=3, search_depth=\"advanced\")\n",
    "\n",
    "@tool\n",
    "def create_pdf_tool(title: str, content: str) -> str:\n",
    "    \"\"\"\n",
    "    Creates a PDF document, parsing structural and inline Markdown (Headers, Bold, Italic)\n",
    "    into formatted PDF elements. Saves to a predictable 'output' folder.\n",
    "    Returns the file path.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # makedirs the output directory \n",
    "        output_dir = \"output\"\n",
    "        os.makedirs(output_dir, exist_ok=True)\n",
    "        \n",
    "        # Create a unique filename within the output directory\n",
    "        # Using a timestamp ensures uniqueness for multiple runs\n",
    "        from datetime import datetime\n",
    "        timestamp = datetime.now().strftime(\"%Y%m%d_%H%M%S\")\n",
    "        safe_title = \"\".join([c for c in title if c.isalnum() or c in (' ', '.', '_')]).replace(' ', '_')[:50]\n",
    "        file_name = f\"{safe_title}_{timestamp}.pdf\"\n",
    "        file_path = os.path.join(output_dir, file_name)\n",
    "\n",
    "        doc = SimpleDocTemplate(file_path, pagesize=letter)\n",
    "        styles = getSampleStyleSheet()\n",
    "\n",
    "        bullet_style = ParagraphStyle(\n",
    "            'BulletStyle',\n",
    "            parent=styles['Normal'],\n",
    "            leftIndent=18,\n",
    "            firstLineIndent=0,\n",
    "            spaceBefore=3,\n",
    "        )\n",
    "\n",
    "        story = [Paragraph(title, styles['Title']), Spacer(1, 12)]\n",
    "\n",
    "        for line in content.split('\\n'):\n",
    "            line = line.strip()\n",
    "            if not line: continue\n",
    "\n",
    "            if line.startswith('===') and line.endswith('==='):\n",
    "                story.append(Paragraph(line.strip('=').strip(), styles['h1']))\n",
    "            elif line.startswith('---') and line.endswith('---'):\n",
    "                story.append(Paragraph(line.strip('-').strip(), styles['h2']))\n",
    "            elif line.startswith('### '):\n",
    "                story.append(Paragraph(line.lstrip('# ').strip(), styles['h3']))\n",
    "            elif line.startswith('- ') or line.startswith('* '):\n",
    "                bullet_text = \"• \" + line[2:]\n",
    "                formatted_line = re.sub(r'\\*\\*(.*?)\\*\\*', r'<b>\\1</b>', bullet_text)\n",
    "                formatted_line = re.sub(r'\\*(.*?)\\*', r'<i>\\1</i>', formatted_line)\n",
    "                story.append(Paragraph(formatted_line, bullet_style))\n",
    "            else:\n",
    "                formatted_line = re.sub(r'\\*\\*(.*?)\\*\\*', r'<b>\\1</b>', line)\n",
    "                formatted_line = re.sub(r'\\*(.*?)\\*', r'<i>\\1</i>', formatted_line)\n",
    "                story.append(Paragraph(formatted_line, styles['Normal']))\n",
    "            \n",
    "            story.append(Spacer(1, 6))\n",
    "                \n",
    "        doc.build(story)\n",
    "        return f\"Successfully created PDF: {os.path.abspath(file_path)}\" \n",
    "    except Exception as e:\n",
    "        return f\"PDF creation failed: {e}\"\n",
    "\n",
    "\n",
    "@tool\n",
    "def create_word_tool(title: str, content: str) -> str:\n",
    "    \"\"\"\n",
    "    Creates a Word document, parsing structural Markdown into Word's\n",
    "    native heading styles. Saves to a predictable 'output' folder.\n",
    "    Returns the file path.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        output_dir = \"output\"\n",
    "        os.makedirs(output_dir, exist_ok=True)\n",
    "\n",
    "        from datetime import datetime\n",
    "        timestamp = datetime.now().strftime(\"%Y%m%d_%H%M%S\")\n",
    "        safe_title = \"\".join([c for c in title if c.isalnum() or c in (' ', '.', '_')]).replace(' ', '_')[:50]\n",
    "        file_name = f\"{safe_title}_{timestamp}.docx\"\n",
    "        file_path = os.path.join(output_dir, file_name)\n",
    "\n",
    "        doc = Document()\n",
    "        doc.add_heading(title, 0) \n",
    "\n",
    "        for line in content.split('\\n'):\n",
    "            line = line.strip()\n",
    "            if not line:\n",
    "                continue\n",
    "\n",
    "            if line.startswith('===') and line.endswith('==='):\n",
    "                doc.add_heading(line.strip('=').strip(), level=1)\n",
    "            elif line.startswith('---') and line.endswith('---'):\n",
    "                doc.add_heading(line.strip('-').strip(), level=2)\n",
    "            elif line.startswith('### '):\n",
    "                doc.add_heading(line.lstrip('# ').strip(), level=3)\n",
    "            elif line.startswith('- ') or line.startswith('* '):\n",
    "                clean_line = line.replace('**', '').replace('*', '')\n",
    "                doc.add_paragraph(clean_line, style='List Bullet')\n",
    "            else:\n",
    "                clean_line = line.replace('**', '').replace('*', '')\n",
    "                doc.add_paragraph(clean_line)\n",
    "\n",
    "        doc.save(file_path)\n",
    "        return f\"Successfully created Word document: {os.path.abspath(file_path)}\" # Return absolute path\n",
    "    except Exception as e:\n",
    "        return f\"Word creation failed: {e}\"\n",
    "\n",
    "print(\"LLM and Tools initialized.\")\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "505e9c3e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Agents and Routers defined.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# --- Specialized Agents ---\n",
    "team3_medical_agent = create_react_agent(llm, [pubmed_tool])\n",
    "team4_financial_agent = create_react_agent(llm, [tavily_tool])\n",
    "\n",
    "# --- Reflection Agent and its Tools ---\n",
    "@tool\n",
    "def continue_research(next_researcher: Literal[\"medical_researcher\", \"financial_researcher\"]) -> str:\n",
    "    \"\"\"Decides to continue research with another specialist to get more information.\"\"\"\n",
    "    return f\"CONTINUE:{next_researcher}\"\n",
    "\n",
    "@tool\n",
    "def complete_research() -> str:\n",
    "    \"\"\"Decides that the research is sufficient and is ready for the reporting phase.\"\"\"\n",
    "    return \"COMPLETE\"\n",
    "\n",
    "reflection_agent = create_react_agent(llm, [continue_research, complete_research])\n",
    "\n",
    "# --- Initial Router to Kick Off the Process ---\n",
    "@tool\n",
    "def initial_research_router(topic: Literal[\"medical_researcher\", \"financial_researcher\"]) -> str:\n",
    "    \"\"\"Selects the best initial researcher to consult for a given query.\"\"\"\n",
    "    return topic\n",
    "\n",
    "initial_router_llm = llm.bind_tools([initial_research_router])\n",
    "\n",
    "print(\"Agents and Routers defined.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "4665bb0b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Node functions defined.\n"
     ]
    }
   ],
   "source": [
    "# These functions are the building blocks of our graph. Each represents a node or a step in the process.\n",
    "\n",
    "def initial_router_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    This is the first step. It analyzes the user's query and decides which\n",
    "    research specialist should be consulted first.\n",
    "    \"\"\"\n",
    "    print(\"--- 👑 Supervisor is choosing the first researcher ---\")\n",
    "    query = state[\"original_query\"]\n",
    "    # The prompt guides the LLM to use the tool correctly.\n",
    "    prompt = f\"Choose the best single initial researcher for this query: '{query}'\"\n",
    "    result = initial_router_llm.invoke(prompt)\n",
    "    \n",
    "    # Default to financial researcher if the LLM fails to choose a tool.\n",
    "    if not result.tool_calls:\n",
    "        print(\"--- Supervisor could not decide, defaulting to financial researcher ---\")\n",
    "        return {\"next_agent\": \"financial_researcher\"}\n",
    "        \n",
    "    chosen_researcher = result.tool_calls[0]['args']['topic']\n",
    "    print(f\"--- Supervisor's choice: {chosen_researcher} ---\")\n",
    "    return {\"next_agent\": chosen_researcher}\n",
    "\n",
    "\n",
    "def medical_research_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    The medical specialist node. It uses the PubMed tool to perform research\n",
    "    and adds its findings and its own name to the state.\n",
    "    \"\"\"\n",
    "    print(\"--- 👨‍⚕️ Medical Researcher at work ---\")\n",
    "    result = team3_medical_agent.invoke({\"messages\": state[\"messages\"]})\n",
    "    \n",
    "    # Update the research results\n",
    "    research_results = state.get(\"research_results\", {})\n",
    "    research_results[\"medical\"] = result[\"messages\"][-1].content\n",
    "    \n",
    "    # Mark this researcher as complete to avoid running it again\n",
    "    completed = state.get(\"completed_researchers\", [])\n",
    "    if \"medical_researcher\" not in completed:\n",
    "        completed.append(\"medical_researcher\")\n",
    "    \n",
    "    return {\"research_results\": research_results, \"completed_researchers\": completed}\n",
    "\n",
    "\n",
    "def financial_research_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    The financial specialist node. It uses the Tavily tool to perform research\n",
    "    and adds its findings and its own name to the state.\n",
    "    \"\"\"\n",
    "    print(\"--- 💰 Financial Researcher at work ---\")\n",
    "    result = team4_financial_agent.invoke({\"messages\": state[\"messages\"]})\n",
    "    \n",
    "    # Update the research results\n",
    "    research_results = state.get(\"research_results\", {})\n",
    "    research_results[\"financial\"] = result[\"messages\"][-1].content\n",
    "    \n",
    "    # Mark this researcher as complete\n",
    "    completed = state.get(\"completed_researchers\", [])\n",
    "    if \"financial_researcher\" not in completed:\n",
    "        completed.append(\"financial_researcher\")\n",
    "        \n",
    "    return {\"research_results\": research_results, \"completed_researchers\": completed}\n",
    "\n",
    "\n",
    "def reflection_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    This is the core of the intelligent loop. It reviews the collected research\n",
    "    and decides whether more research is needed or if it's time to report.\n",
    "    \"\"\"\n",
    "    print(\"--- 🤔 Reviewer is reflecting on the results ---\")\n",
    "    original_query = state[\"original_query\"]\n",
    "    research_results = state[\"research_results\"]\n",
    "    completed_researchers = state[\"completed_researchers\"]\n",
    "    \n",
    "    # Determine which researchers are still available.\n",
    "    all_researchers = [\"medical_researcher\", \"financial_researcher\"]\n",
    "    available_researchers = [r for r in all_researchers if r not in completed_researchers]\n",
    "    \n",
    "    prompt = f\"\"\"\n",
    "    The user's original query was: \"{original_query}\"\n",
    "\n",
    "    So far, the following research has been gathered:\n",
    "    {json.dumps(research_results, indent=2)}\n",
    "\n",
    "    The following researchers have already contributed: {completed_researchers}\n",
    "\n",
    "    Based on the query and the research, is the information sufficient to create a complete report?\n",
    "\n",
    "    - If YES, the research is complete. Use the `complete_research` tool.\n",
    "    - If NO, and there are researchers available to consult ({available_researchers}), choose the best one to consult next using the `continue_research` tool.\n",
    "    - If NO, but there are no more researchers available, you must use the `complete_research` tool as we have to proceed with the information we have.\n",
    "    \"\"\"\n",
    "    \n",
    "    result = reflection_agent.invoke({\"messages\": [HumanMessage(prompt)]})\n",
    "    decision = result[\"messages\"][-1].content\n",
    "    \n",
    "    # Parse the agent's decision to control the loop\n",
    "    if \"CONTINUE\" in decision:\n",
    "        next_agent = decision.split(\":\")[1]\n",
    "        # Ensure we don't route to an unavailable agent\n",
    "        if next_agent in available_researchers:\n",
    "            print(f\"--- Reflector Decision: Continue with {next_agent} ---\")\n",
    "            return {\"next_agent\": next_agent}\n",
    "\n",
    "    print(\"--- Reflector Decision: Research is complete, proceeding to reporting ---\")\n",
    "    return {\"next_agent\": \"reporting_node\"}\n",
    "\n",
    "\n",
    "def reporting_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    This node takes all the final research and formats it into a single,\n",
    "    comprehensive text block for the document creation step.\n",
    "    \"\"\"\n",
    "    print(\"--- 📝 Report Generator at work ---\")\n",
    "    report_text = f\"Final Report for Query: {state['original_query']}\\n\\n\"\n",
    "    report_text += \"=== EXECUTIVE SUMMARY & FINDINGS ===\\n\\n\"\n",
    "    \n",
    "    # format the JSON research results into the report string\n",
    "    for researcher, findings in state.get(\"research_results\", {}).items():\n",
    "        report_text += f\"--- {researcher.replace('_', ' ').title()} ---\\n\"\n",
    "        report_text += f\"{findings}\\n\\n\"\n",
    "        \n",
    "    return {\"report\": report_text}\n",
    "\n",
    "\n",
    "def document_creation_node(state: AgentState) -> Dict[str, Any]:\n",
    "    \"\"\"\n",
    "    The final step. This node uses the generated report text to create\n",
    "    both a PDF and a Word document by calling the tools directly for reliability.\n",
    "    \"\"\"\n",
    "    print(\"--- 📄 Document Creator at work (Direct Calling) ---\")\n",
    "    document_title = f\"Research Report: {state['original_query']}\"\n",
    "    content = state['report']\n",
    "    \n",
    "    # Call tools directly to avoid LLM errors\n",
    "    pdf_result = create_pdf_tool.invoke({\n",
    "        \"title\": document_title,\n",
    "        \"content\": content\n",
    "    })\n",
    "    \n",
    "    word_result = create_word_tool.invoke({\n",
    "        \"title\": document_title,\n",
    "        \"content\": content\n",
    "    })\n",
    "    \n",
    "    final_output_str = f\"Document generation complete.\\n- {pdf_result}\\n- {word_result}\"\n",
    "    \n",
    "    return {\"final_output\": final_output_str}\n",
    "\n",
    "print(\"Node functions defined.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "70229cec",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Graph compiled successfully!\n"
     ]
    }
   ],
   "source": [
    "# define the graph structure and wire all the nodes together.\n",
    "\n",
    "workflow = StateGraph(AgentState)\n",
    "\n",
    "# Add all the nodes to the graph\n",
    "workflow.add_node(\"initial_router\", initial_router_node)\n",
    "workflow.add_node(\"medical_researcher\", medical_research_node)\n",
    "workflow.add_node(\"financial_researcher\", financial_research_node)\n",
    "workflow.add_node(\"reflection_node\", reflection_node)\n",
    "workflow.add_node(\"reporting_node\", reporting_node)\n",
    "workflow.add_node(\"document_creation_node\", document_creation_node)\n",
    "\n",
    "# Set the entry point of the graph\n",
    "workflow.set_entry_point(\"initial_router\")\n",
    "\n",
    "# Define the conditional routing logic\n",
    "def route_after_initial_router(state: AgentState) -> str:\n",
    "    \"\"\"Routes to the first researcher chosen by the supervisor.\"\"\"\n",
    "    return state[\"next_agent\"]\n",
    "\n",
    "def route_after_reflection(state: AgentState) -> str:\n",
    "    \"\"\"\n",
    "    Determines the next step after the reflection node has made a decision.\n",
    "    This can either loop back to another researcher or proceed to reporting.\n",
    "    \"\"\"\n",
    "    next_agent = state[\"next_agent\"]\n",
    "    if next_agent == \"reporting_node\":\n",
    "        return \"proceed_to_reporting\"\n",
    "    else:\n",
    "        return \"continue_research\"\n",
    "\n",
    "# Wire the edges\n",
    "# The initial router decides which researcher to call first.\n",
    "workflow.add_conditional_edges(\n",
    "    \"initial_router\",\n",
    "    route_after_initial_router,\n",
    "    {\n",
    "        \"medical_researcher\": \"medical_researcher\",\n",
    "        \"financial_researcher\": \"financial_researcher\",\n",
    "    }\n",
    ")\n",
    "\n",
    "# After any research node finishes, it always goes to the reflection node to be reviewed.\n",
    "workflow.add_edge(\"medical_researcher\", \"reflection_node\")\n",
    "workflow.add_edge(\"financial_researcher\", \"reflection_node\")\n",
    "\n",
    "# The reflection node is the heart of the loop.\n",
    "workflow.add_conditional_edges(\n",
    "    \"reflection_node\",\n",
    "    route_after_reflection,\n",
    "    {\n",
    "        # If the decision is to continue, this edge maps the next agent's name\n",
    "        # to the correct node, creating the loop.\n",
    "        \"continue_research\": \"initial_router\", # Go back to the router to select the next researcher\n",
    "        # If the decision is to proceed, we move to the reporting phase.\n",
    "        \"proceed_to_reporting\": \"reporting_node\",\n",
    "    }\n",
    ")\n",
    "\n",
    "# The reporting phase is a straight line to the end.\n",
    "workflow.add_edge(\"reporting_node\", \"document_creation_node\")\n",
    "workflow.add_edge(\"document_creation_node\", END)\n",
    "\n",
    "\n",
    "# Compile the graph into a runnable application.\n",
    "# The MemorySaver allows the graph to be stateful and remember conversation history.\n",
    "memory = MemorySaver()\n",
    "app = workflow.compile(checkpointer=memory)\n",
    "\n",
    "print(\"Graph compiled successfully!\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "9994adea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from IPython.display import Image, display\n",
    "display(Image(app.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "49a32c32",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Running Query: 'Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies' ---\n",
      "--- Watching the Reflective Loop in Action ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={}\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {},\n",
      "  \"completed_researchers\": [],\n",
      "  \"report\": \"\",\n",
      "  \"final_output\": \"\"\n",
      "}\n",
      "==================================================\n",
      "--- 👑 Supervisor is choosing the first researcher ---\n",
      "--- Supervisor's choice: financial_researcher ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={}\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {},\n",
      "  \"completed_researchers\": [],\n",
      "  \"report\": \"\",\n",
      "  \"final_output\": \"\",\n",
      "  \"next_agent\": \"financial_researcher\"\n",
      "}\n",
      "==================================================\n",
      "--- 💰 Financial Researcher at work ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={} id='3c3c35e9-9c1e-43cf-9ca0-c37984986ab3'\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {\n",
      "    \"financial\": \"The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\"\n",
      "  },\n",
      "  \"completed_researchers\": [\n",
      "    \"financial_researcher\"\n",
      "  ],\n",
      "  \"report\": \"\",\n",
      "  \"final_output\": \"\",\n",
      "  \"next_agent\": \"financial_researcher\"\n",
      "}\n",
      "==================================================\n",
      "--- 🤔 Reviewer is reflecting on the results ---\n",
      "--- Reflector Decision: Research is complete, proceeding to reporting ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={} id='3c3c35e9-9c1e-43cf-9ca0-c37984986ab3'\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {\n",
      "    \"financial\": \"The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\"\n",
      "  },\n",
      "  \"completed_researchers\": [\n",
      "    \"financial_researcher\"\n",
      "  ],\n",
      "  \"report\": \"\",\n",
      "  \"final_output\": \"\",\n",
      "  \"next_agent\": \"reporting_node\"\n",
      "}\n",
      "==================================================\n",
      "--- 📝 Report Generator at work ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={} id='3c3c35e9-9c1e-43cf-9ca0-c37984986ab3'\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {\n",
      "    \"financial\": \"The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\"\n",
      "  },\n",
      "  \"completed_researchers\": [\n",
      "    \"financial_researcher\"\n",
      "  ],\n",
      "  \"report\": \"Final Report for Query: Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\n\\n=== EXECUTIVE SUMMARY & FINDINGS ===\\n\\n--- Financial ---\\nThe market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\\n\\n\",\n",
      "  \"final_output\": \"\",\n",
      "  \"next_agent\": \"reporting_node\"\n",
      "}\n",
      "==================================================\n",
      "--- 📄 Document Creator at work (Direct Calling) ---\n",
      "\n",
      "==================================================\n",
      "Node Output:\n",
      "{\n",
      "  \"messages\": [\n",
      "    \"content=\\\"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\\" additional_kwargs={} response_metadata={} id='3c3c35e9-9c1e-43cf-9ca0-c37984986ab3'\"\n",
      "  ],\n",
      "  \"original_query\": \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\",\n",
      "  \"research_results\": {\n",
      "    \"financial\": \"The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\"\n",
      "  },\n",
      "  \"completed_researchers\": [\n",
      "    \"financial_researcher\"\n",
      "  ],\n",
      "  \"report\": \"Final Report for Query: Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\\n\\n=== EXECUTIVE SUMMARY & FINDINGS ===\\n\\n--- Financial ---\\nThe market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\\n\\n\",\n",
      "  \"final_output\": \"Document generation complete.\\n- Successfully created PDF: /Users/myatkaung/Desktop/LLM_PROJECTS/AgenticAI/3-langgraph/Assignments/04_Assignment/output/Research_Report_Analyze_the_market_impact_of_new_A_20250704_202744.pdf\\n- Successfully created Word document: /Users/myatkaung/Desktop/LLM_PROJECTS/AgenticAI/3-langgraph/Assignments/04_Assignment/output/Research_Report_Analyze_the_market_impact_of_new_A_20250704_202744.docx\",\n",
      "  \"next_agent\": \"reporting_node\"\n",
      "}\n",
      "==================================================\n",
      "\n",
      "\n",
      "--- ✅ Process Complete ---\n",
      "Final Research Results Gathered:\n",
      "{\n",
      "  \"financial\": \"The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\\n\\n### **1. Market Growth Projections**\\n- **Market Size**: The global Alzheimer\\u2019s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\\n- **Key Drivers**: \\n  - Rising prevalence of Alzheimer\\u2019s, particularly among women and the elderly.\\n  - Advances in R&D for disease-modifying therapies.\\n  - Growing healthcare spending on neurodegenerative diseases.\\n\\n### **2. Impact of New Treatments**\\n- **Lecanemab (Leqembi)**: The FDA\\u2019s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer\\u2019s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\\n- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer\\u2019s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\\n\\n### **3. Competitive Landscape**\\n- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\\n- **Challenges**: \\n  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\\n  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\\n  - Competition from generic alternatives for older treatments.\\n\\n### **4. Long-Term Opportunities**\\n- **Aging Population**: By 2050, Alzheimer\\u2019s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\\n- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\\n- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer\\u2019s rises.\\n\\n### **5. Risks and Mitigation**\\n- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\\n- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\\n- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\\n\\n### **Conclusion**\\nPharmaceutical companies investing in Alzheimer\\u2019s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\"\n",
      "}\n",
      "\n",
      "Final Report Text:\n",
      "Final Report for Query: Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\n",
      "\n",
      "=== EXECUTIVE SUMMARY & FINDINGS ===\n",
      "\n",
      "--- Financial ---\n",
      "The market impact of new Alzheimer's drug treatments on pharmaceutical companies is significant, driven by rising demand, regulatory approvals, and competitive innovation. Here's a structured analysis based on recent data:\n",
      "\n",
      "### **1. Market Growth Projections**\n",
      "- **Market Size**: The global Alzheimer’s therapeutics market is projected to grow from **$5.7 billion in 2025 to $12.07 billion by 2034**, at a **CAGR of 8.7%** (Towards Healthcare, 2023). This growth is fueled by aging populations, increased prevalence (6.7 million Americans aged 65+ in 2023), and demand for personalized treatments.\n",
      "- **Key Drivers**: \n",
      "  - Rising prevalence of Alzheimer’s, particularly among women and the elderly.\n",
      "  - Advances in R&D for disease-modifying therapies.\n",
      "  - Growing healthcare spending on neurodegenerative diseases.\n",
      "\n",
      "### **2. Impact of New Treatments**\n",
      "- **Lecanemab (Leqembi)**: The FDA’s 2023 full approval of lecanemab, which slows cognitive decline in early-stage Alzheimer’s, marks a milestone. Companies like **Eisai and Biogen** (co-developers) are likely to see revenue growth, though high costs and reimbursement challenges may limit short-term adoption.\n",
      "- **Pipeline Expansion**: Over 50 pharmaceutical companies (e.g., Merck, Roche, Janssen) are actively developing Alzheimer’s drugs, per PubMed data. This competitive landscape drives innovation but increases R&D costs and risks of clinical trial failures.\n",
      "\n",
      "### **3. Competitive Landscape**\n",
      "- **Market Leaders**: Biogen, Eisai, and Roche dominate due to approved or late-stage pipeline drugs. Smaller firms like **Cassava Sciences** and **Denali Therapeutics** are also gaining traction with novel mechanisms (e.g., amyloid-beta and tau-targeting therapies).\n",
      "- **Challenges**: \n",
      "  - High R&D costs ($2.6 billion average per drug) and regulatory hurdles.\n",
      "  - Pricing pressures from payers and governments, especially for expensive therapies like lecanemab ($26,000/year).\n",
      "  - Competition from generic alternatives for older treatments.\n",
      "\n",
      "### **4. Long-Term Opportunities**\n",
      "- **Aging Population**: By 2050, Alzheimer’s cases in the U.S. could reach 12.7 million, creating sustained demand for treatments.\n",
      "- **Personalized Medicine**: Advances in biomarkers and genetic research enable targeted therapies, allowing companies to capture niche markets with higher margins.\n",
      "- **Global Expansion**: Emerging markets (e.g., China, India) offer growth as healthcare infrastructure improves and awareness of Alzheimer’s rises.\n",
      "\n",
      "### **5. Risks and Mitigation**\n",
      "- **Clinical Risks**: Many pipeline drugs face high failure rates. Diversifying R&D portfolios and collaborating with academia can reduce risks.\n",
      "- **Regulatory Scrutiny**: Post-approval studies (e.g., for lecanemab) may reveal safety concerns, impacting adoption. Transparent communication with regulators is critical.\n",
      "- **Pricing Pressures**: Governments may impose price controls. Companies can offset this by emphasizing cost-effectiveness (e.g., reducing long-term care costs).\n",
      "\n",
      "### **Conclusion**\n",
      "Pharmaceutical companies investing in Alzheimer’s therapies are poised to benefit from a rapidly expanding market, but success depends on navigating R&D challenges, securing favorable reimbursement terms, and differentiating products in a competitive space. Firms with robust pipelines and partnerships (e.g., Biogen-Eisai, Roche-Genentech) are best positioned to capitalize on this growth.\n",
      "\n",
      "\n",
      "\n",
      "Final Output (Document Paths):\n",
      "Document generation complete.\n",
      "- Successfully created PDF: /Users/myatkaung/Desktop/LLM_PROJECTS/AgenticAI/3-langgraph/Assignments/04_Assignment/output/Research_Report_Analyze_the_market_impact_of_new_A_20250704_202744.pdf\n",
      "- Successfully created Word document: /Users/myatkaung/Desktop/LLM_PROJECTS/AgenticAI/3-langgraph/Assignments/04_Assignment/output/Research_Report_Analyze_the_market_impact_of_new_A_20250704_202744.docx\n"
     ]
    }
   ],
   "source": [
    "# The complex query that requires both medical and financial research.\n",
    "complex_query = \"Analyze the market impact of new Alzheimer's drug treatments on pharmaceutical companies\"\n",
    "\n",
    "# The config for this specific run. The thread_id ensures this conversation is isolated.\n",
    "config = {\"configurable\": {\"thread_id\": \"reflective-loop-run-1\"}}\n",
    "\n",
    "# The initial state for the graph.\n",
    "initial_state = {\n",
    "    \"messages\": [HumanMessage(content=complex_query)],\n",
    "    \"original_query\": complex_query,\n",
    "    \"research_results\": {},\n",
    "    \"completed_researchers\": [],\n",
    "    \"report\": \"\",\n",
    "    \"final_output\": \"\"\n",
    "}\n",
    "\n",
    "print(f\"--- Running Query: '{complex_query}' ---\")\n",
    "print(\"--- Watching the Reflective Loop in Action ---\")\n",
    "\n",
    "try:\n",
    "    # Use app.stream() to see the output from each node as it executes.\n",
    "    for event in app.stream(initial_state, config=config, stream_mode=\"values\"):\n",
    "        print(\"\\n\" + \"=\"*50)\n",
    "        print(f\"Node Output:\\n{json.dumps(event, indent=2, default=str)}\")\n",
    "        print(\"=\"*50)\n",
    "\n",
    "    final_state = app.get_state(config)\n",
    "    \n",
    "    print(\"\\n\\n--- ✅ Process Complete ---\")\n",
    "    print(\"Final Research Results Gathered:\")\n",
    "    print(json.dumps(final_state.values['research_results'], indent=2))\n",
    "    print(\"\\nFinal Report Text:\")\n",
    "    print(final_state.values['report'])\n",
    "    print(\"\\nFinal Output (Document Paths):\")\n",
    "    print(final_state.values['final_output'])\n",
    "\n",
    "except Exception as e:\n",
    "    print(f\"\\n--- 🚨 An Error Occurred ---\")\n",
    "    print(f\"Error: {e}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "eca39911",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
